What is peptide therapy? Three categories that matter

Peptide therapy is a term that has expanded faster than its definition. As of 2026 it covers three things at once: FDA-approved peptide medicines that have been clinical mainstream for over a century, compounded peptides that the February 2026 HHS reclassification just reopened a grey zone for, and research-only peptides that sit outside any approved framework. Most articles use the phrase as if all three are the same. They are not, and the distinctions matter for any reader deciding whether to take one.

Peptide therapy is not a medical specialty, it is a marketing umbrella over three different categories#

There is no formal medical specialty called peptide therapy. The phrase first entered cosmetic dermatology and longevity-clinic marketing in the 2010s, and by 2024 it had spread to wellness clinics, online retailers, and grey-market vendors who use it interchangeably for very different things. Walking into one clinic that advertises peptide therapy might mean a semaglutide weight-loss prescription. Walking into another might mean a vial of BPC-157 sourced from a research chemical supplier with no clinical oversight. The marketing is similar; the regulatory and clinical reality is not.

The honest framing is that peptide therapy in 2026 is shorthand for three distinct categories of compounds: FDA-approved peptide medicines (semaglutide, tirzepatide, tesamorelin, and roughly 80 others); compounded peptides produced under 503A or 503B pharmacy oversight with a physician's prescription; and research-only peptides that have no approved clinical use and are typically labeled "for research purposes only." Each category has its own regulatory pathway, its own evidence base, and its own risk profile. Treating them as interchangeable is the most common mistake readers make when researching peptide therapy.

This guide separates the three. Peptide therapy explained from the regulatory side is the cleanest entry into the topic, because the regulatory category determines almost everything else about a given peptide: whether a prescription can be filled, whether the safety data exists, whether the use case is supported by clinical trials, and whether the product can legally enter Norway by any route. Peptide therapy 2026 looks different from peptide therapy 2024 mostly because of the February 2026 HHS reclassification, and that one event sits at the centre of why the term is currently confusing. The rest of this guide covers what that 2026 regulatory shift actually changed (less than the headlines suggest) and how the Norwegian framework differs from the US one in ways that matter for any reader inside DMP's jurisdiction.

FDA-approved peptide medicines have been the regulatory mainstream since insulin in 1921#

The first peptide drug commercialized was insulin, isolated by Frederick Banting in 1921 and brought to market in 1923 (Henninot, Collins, and Nuss, PMC10967573). It established a regulatory pathway that has produced more than 80 approved peptide drugs in the century since, with 33 non-insulin peptides approved since 2000 and over 170 currently in clinical development (Wang et al., Signal Transduction and Targeted Therapy 2022, PMC8844085).

The categories these approved peptides span are wide: metabolic disorders (insulin analogs, GLP-1 agonists), oncology (peptide-drug conjugates and antibody-drug conjugates with peptide payloads), cardiovascular and renal indications (vasopressin analogs), gastrointestinal (octreotide for acromegaly), urology and reproductive medicine (GnRH analogs), pain management, and antimicrobial applications. The 2025 FDA TIDES (Therapeutic Innovation in Drugs Endorsing Synthesis) harvest added four more approvals including elamipretide, the first disease-specific medicine cleared for Barth syndrome (Pharmaceuticals 2025, PMC12943124).

FDA approved peptides span both these high-volume metabolic indications and a long tail of narrower clinical uses. For most patients, the practical face of peptide therapy in 2026 is the GLP-1 class. Semaglutide (marketed as Ozempic for type 2 diabetes, Wegovy for obesity, and Rybelsus as the oral version) reached 14.9% mean weight loss at 68 weeks in STEP-1 (NEJM 2021). Tirzepatide, a dual GIP/GLP-1 receptor agonist marketed as Mounjaro for diabetes and Zepbound for obesity, reached 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (NEJM 2022). These are FDA-approved, EMA-authorized, and in Norway DMP-registered medicines available by prescription. They are the unambiguous "peptide therapy."

A second tier of approved peptides covers narrower indications. Tesamorelin (marketed as Egrifta) is FDA-approved for HIV-associated lipodystrophy. Octreotide is approved for acromegaly. GnRH analogs are approved for prostate cancer and endometriosis. These are not what the wellness market typically means when it advertises peptide therapy, but they are the regulatory ground truth: peptides that have completed Phase 1, 2, and 3 trials, demonstrated safety and efficacy for a defined indication, and earned formal approval from regulators. For a worked example of how an approved GLP-1 peptide is used in practice, see Klarovel's semaglutide guide.

Compounded peptides occupy the FDA's 503A grey zone that the February 2026 HHS reclassification reopened#

The middle category is the most legally complex, and the most affected by recent regulatory news. Compounded peptides are produced by 503A or 503B pharmacies, which are licensed to prepare individualized medications using bulk drug substances when a commercial product is not available or appropriate for a specific patient. Compounding pharmacies have a long history with peptides; they prepared insulin variants, hormone replacement therapies, and other peptide formulations long before commercial alternatives existed.

The FDA maintains two lists for bulk drug substances used in compounding. Category 1 includes substances the agency considers safe enough to compound under 503A or 503B oversight. Category 2 is the do-not-compound list, reserved for substances the FDA has flagged as presenting significant safety risks. In late 2023 the FDA placed BPC-157, Thymosin α1 (TA-1), and several other popular peptides on Category 2, citing concerns about immune reactions, peptide impurities, and absent human safety data (FDA bulk drug substances list).

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 of those 19 peptides would be moved back to Category 1 (BioPharma Dive, 2026). The procedural mechanism is that the companies which originally nominated the peptides for Category 2 review have withdrawn their nominations. Those peptides come off Category 2 effective April 23, 2026. The FDA's Pharmacy Compounding Advisory Committee will meet July 23 and 24, 2026, to review whether to formally clear any of them for compounding under 503A or 503B oversight.

The critical thing to understand about this reclassification is what it does not mean. Reclassification to Category 1 is not the same as FDA drug approval. Approved peptide drugs (the semaglutides, tirzepatides, tesamorelins) have completed Phase 1, 2, and 3 clinical trials demonstrating safety and efficacy for specific indications. Reclassified compounded peptides have not. They become eligible for compounding under physician prescription, but they remain prescription therapeutics used at physician discretion based on individual patient assessment, not approved medicines with proven efficacy for any specific indication.

The practical implication for a US patient: after April 23, 2026, a 503A pharmacy with a valid prescription from a licensed provider may be able to legally compound a reclassified peptide, assuming the FDA clears it after the July 2026 advisory committee review. Before that date, the same prescription cannot be filled at a compounding pharmacy. The peptide is not approved; it is permitted to be compounded.

Research-only peptides like BPC-157, TB-500, and the rest sit outside any approved framework#

The third category is the largest by search volume and the smallest by clinical evidence. Research peptides are compounds that have biological activity in cell culture, animal models, or early-stage human studies, but have not progressed through the formal drug approval process. They are typically sold by chemical suppliers with labels indicating "for research purposes only, not for human consumption." That label is the regulatory mechanism that allows the compounds to ship through international postal channels in many jurisdictions.

The list of research-only peptides is long: BPC-157, TB-500 (thymosin beta-4 fragment), CJC-1295 (with and without DAC), Ipamorelin, AOD-9604, GHK-Cu in injectable form, Melanotan II, KPV, Selank, Semax, MOTS-c, Epitalon, and many others. None of these have FDA, EMA, or DMP marketing authorization for any indication. The 2026 HHS reclassification is moving some of them out of Category 2 (so 503A pharmacies may be able to compound them under prescription), but reclassification still does not mean approval.

The clinical evidence base for research-only peptides varies widely. BPC-157 has decades of preclinical data on connective tissue repair and a small number of human pilot studies, but no Phase 3 trials; the published research is summarised in Klarovel's BPC-157 guide. Semax and Selank have decades of Russian clinical use but no FDA, EMA, or DMP approvals; the data was never submitted for Western regulatory review. TB-500 has preclinical evidence for cardiovascular and wound-healing applications but has not been tested in registered Phase 3 human trials. The honest framing for any research-only peptide is that the mechanism may be plausible, the preclinical signal may be real, and the human data is thin or absent.

Research-only does not mean unsafe. It means undocumented. Many of these peptides have been used in research-use protocols for years without major adverse events, but adverse-event reporting outside formal clinical trial frameworks is also absent. The risk profile is uncharacterized in a way that approved medicines are not.

In Norway, peptidterapi as a clinical category barely exists outside DMP-approved GLP-1 medicines#

The Norwegian regulatory framework differs from the US one in ways that matter for any reader inside DMP's jurisdiction. Direktoratet for medisinske produkter (DMP, the Norwegian Medical Products Agency) is the authority that determines whether a product is classified as a pharmaceutical, foodstuff, cosmetic, or doping agent. Its definition of a pharmaceutical is broad: any substance presented as suitable for handling disease, alleviating symptoms, or affecting physiological functions through pharmacological, immunological, or metabolic effect (DMP Klassifisering av legemidler).

Under that framework, the GLP-1 medicines (semaglutide as Wegovy and Ozempic, tirzepatide as Mounjaro) are DMP-registered pharmaceuticals available by prescription. Tesamorelin under the Egrifta brand is registered for HIV-associated lipodystrophy. A small number of older approved peptides (insulin analogs, vasopressin, oxytocin) are also registered. These represent the practical scope of "peptidterapi" that a Norwegian resident can access through the apotek (pharmacy) system.

Everything else falls into a different category. Compounded peptides under US 503A pharmacy oversight have no Norwegian equivalent in the same regulatory form. The Norwegian apotek system does not compound peptides like BPC-157 even with a prescription. Research-only peptides imported by post are subject to forskrift 2004-11-02-1441 § 3-2, which prohibits postal import of unregistered medicines. Tolletaten enforces this by intercepting shipments at the border, regardless of how the package is labeled. For the full Norwegian regulatory picture, see Klarovel's guide on the legal status of peptides in Norway.

The grey-market route that operates in the US, where research peptides are ordered from chemical suppliers and self-injected, is not a legal route in Norway. It exists in practice, and Norwegian newsrooms have covered the rise of grey-market peptide injection trends on TikTok aimed at younger users (VG: Ulovlige sprøyter tar av i sosiale medier, 2024), but the regulatory framework treats it as illegal import of unregistered medicines, not as an approved alternative pathway.

The practical effect for Norwegian patients researching peptide therapy: the term most accurately covers GLP-1 medicines available on resept (prescription), with everything else operating outside the apotek-and-DMP framework Norwegian residents are otherwise familiar with.

The honest reader's framework: what makes a peptide actually therapy, not an experiment#

Three questions separate peptide therapy from peptide experimentation, and they apply equally in the US, the EU, and Norway.

First, is the compound approved by the relevant regulator (FDA, EMA, DMP) for the indication it is being used for? Approved means Phase 1, 2, and 3 trials demonstrating safety and efficacy, formal regulatory review, post-marketing surveillance, and ongoing pharmacovigilance. Semaglutide for obesity meets this bar. BPC-157 for tendon repair does not, anywhere in the world as of 2026.

Second, if the compound is being prescribed for an off-label use, is the off-label use itself supported by clinical evidence? Tesamorelin prescribed off-label for general visceral fat reduction, rather than HIV-associated lipodystrophy, sits in this territory. The compound is approved; the indication is off-label; the practitioner is taking responsibility for the clinical judgment. Studies have shown that off-label use of an approved peptide carries different evidence weight than approved on-label use, and the responsibility for the off-label decision belongs to the prescriber.

Third, if the compound is being compounded under 503A pharmacy oversight (in jurisdictions where that pathway exists), what is the prescriber's documented clinical rationale, and what monitoring is in place? A reasonable rationale exists for some compounded peptides; for others it does not. The 2026 reclassification expands the pool of compounds that can move through this pathway in the US, but it does not expand the evidence base that supports any particular clinical use.

A peptide that fails all three questions, that is not approved anywhere for any indication, that is not being compounded under physician oversight, and that is being used based on internet protocols and self-administration, is not peptide therapy in any meaningful sense. It is a research compound being self-administered. The semantic distinction matters because the risk profile is fundamentally different. Approved medicines have known safety signals associated with documented adverse-event databases; off-label use of approved medicines has rough analogues. Research compound self-administration has neither.

Klarovel's editorial position is that the term peptide therapy should be reserved for the first two categories: approved medicines used for approved or off-label indications under physician oversight. The third category is research, not therapy, and labeling it otherwise misleads readers.

Frequently asked questions about peptide therapy#

What does peptide therapy actually mean? Peptide therapy is a marketing umbrella that covers three different categories of compounds in 2026: FDA-approved peptide medicines (such as semaglutide, tirzepatide, and tesamorelin), compounded peptides produced by 503A pharmacies under physician prescription, and research-only peptides that have no approved clinical use. The term is often used as if all three are the same; the regulatory and clinical reality is not.

Are peptides FDA-approved? Yes, in specific cases. More than 80 peptide drugs hold FDA approval as of 2026, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta), elamipretide for Barth syndrome, and many others. Roughly 33 non-insulin peptides have been approved since 2000, and over 170 are in active clinical development. Research-only peptides like BPC-157, TB-500, Selank, and Semax are not FDA-approved for any indication.

What does the 2026 FDA peptide reclassification actually change? In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 of 19 peptides on the FDA's Category 2 do-not-compound list would be moved back to Category 1, effective April 23, 2026. This means 503A and 503B compounding pharmacies in the US may be able to use those peptides as bulk drug substances to prepare individualized prescriptions, after the FDA's Pharmacy Compounding Advisory Committee reviews them at its July 2026 meeting. Reclassification is not the same as FDA drug approval; the peptides have not completed clinical trials demonstrating safety and efficacy for specific indications.

Is peptide therapy legal in Norway? The answer depends on which peptide. GLP-1 medicines (Wegovy, Ozempic, Mounjaro), Tesamorelin (Egrifta) for HIV-lipodystrophy, and a small number of older approved peptides are DMP-registered and available on prescription through the apotek system. Research-only peptides imported by post are subject to forskrift 2004-11-02-1441 § 3-2, which Tolletaten enforces by intercepting unregistered medicine shipments at the border. The compounding-pharmacy pathway that exists in the US is not part of the Norwegian framework.

How do I know if a peptide is actually therapy versus an experiment? Three questions separate the two. Is the compound approved by FDA, EMA, or DMP for the indication you want? Is any off-label use supported by clinical evidence? Is the compound being compounded under documented physician oversight with a clear rationale and monitoring plan? A peptide that fails all three is a research compound being self-administered, not therapy. Research has shown that approved medicines carry characterised safety profiles and post-marketing surveillance; research-compound self-administration has neither.

Where Klarovel sits in the peptide therapy framework#

Klarovel's editorial scope is intentionally narrow. The site covers approved peptide medicines (the GLP-1 class, Tesamorelin, the older insulin and hormone analogs) with the same evidence-graded framing that any clinical guide would apply. It also covers compounded and research peptides where the pharmacology is real and the regulatory status warrants explicit framing, because Norwegian readers researching the topic encounter both categories in social-media coverage, fitness forums, and grey-market vendor sites. Treating those categories with editorial silence does not make them go away; it just leaves readers without a Norwegian-language resource that names the distinctions clearly.

The questionnaire and protocol engine on Klarovel's product side are designed for the approved-medicine track. The engine maps a reader's biomarker panel and goal profile to specific peptide medicines that have FDA, EMA, or DMP authorisation for the relevant indication, with explicit screening for contraindications. Klarovel does not sell peptides directly; products available through the partner catalog are dispensed by research-use suppliers, with the regulatory framing explained on the disclosures page.

For readers deciding whether peptide therapy is appropriate for them, the structured route is to start with the questionnaire, which maps health profile and goals to evidence-supported peptide options. The reconstitution calculator handles dosing math when an approved or compounded peptide is part of a protocol. The how-it-works page explains the broader engine and clinical-review pipeline.

Peptide therapy is real; it is also more narrowly defined than the wellness market suggests. Reading the term carefully is the first step in deciding whether any specific compound deserves your attention.